NATCOPHARM vs ORCHPHARMA: Stock Comparison
NATCO PHARMA is the larger company by market capitalisation. NATCO PHARMA shows a lower P/E, a higher ROE and a higher dividend yield, while ORCHID PHARMA shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NATCOPHARM leads 10; ORCHPHARMA leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NATCOPHARM | ORCHPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NATCOPHARM | ORCHPHARMA |
|---|---|---|
| Live Price | ₹815.35 | ₹1,003.05 |
| Day Change | -0.4% | -1.28% |
| Volume | 5.68 L | 68,916 |
| 52-Week High | ₹1,226.8 | ₹1,133 |
| 52-Week Low | ₹789 | ₹480 |
| Distance from 52W High | -33.54% | -11.47% |
Valuation
| Metric | NATCOPHARM | ORCHPHARMA |
|---|---|---|
| Market Cap | ₹14,669 Cr | ₹5,123 Cr |
| P/E Ratio | 12.82x | 478.67x |
| P/B Ratio | 1.59x | 3.27x |
| EPS | ₹11.53 | ₹2.35 |
| Book Value | ₹514.83 | ₹308.43 |
| Dividend Yield | 0.55% | 0% |
Growth
| Metric | NATCOPHARM | ORCHPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | -39.6% | -1.5% |
| EPS Growth (TTM YoY) | -34.1% | 0% |
| Qtr Sales Growth | 23.23% | 0% |
| Qtr Profit Growth | 176.81% | 270.21% |
Profitability & Leverage
| Metric | NATCOPHARM | ORCHPHARMA |
|---|---|---|
| ROE | 14.98% | 3.3% |
| ROCE | 14.19% | 3.77% |
| Net Margin | 34.78% | 2.51% |
| Operating Margin | 38.85% | 7.2% |
| Debt to Equity | 0.08x | 0.13x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NATCOPHARM | ORCHPHARMA |
|---|---|---|
| Promoter Holding | 49.14% | 69.84% |
| FII Holding | 16.99%▼ 0.38 pp | 0.81%▼ 0.06 pp |
| DII Holding | 5.62%▲ 0.16 pp | 20.75%▲ 0.5 pp |
| Public Holding | 27.97%▲ 0.22 pp | 8.61%▼ 0.44 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NATCO PHARMA and ORCHID PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.